{
  "CBAV.MC": {
    "city": "Madrid",
    "country": "Spain",
    "currency": "EUR",
    "exchange": "MCE",
    "industry": "Diagnostics & Research",
    "long_name": "Clínica Baviera, S.A.",
    "market": "es_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "CLINICA BAVIERA S.A.",
    "state": null,
    "summary": "ClÃ­nica Baviera, S.A. operates a network of ophthalmological clinics. It is involved in the diagnosis, treatment, and monitoring of various types of ophthalmological disorders. The company's clinics offers myopia, hyperopia, astigmatism, presbyopia, cataract, retina, pediatric ophthalmology, glaucoma, squint, oculoplasty, cornea, neuroftalmologÃ­a, and vias lagrimales treatments, as well as refractive surgery services. It operates approximately 80 ophthalmological clinics in Spain, Germany, Austria, and Italy. The company is based in Madrid, Spain.",
    "website": "http://www.clinicabaviera.com",
    "zipcode": "28046"
  },
  "D9Z.F": {
    "city": "Madrid",
    "country": "Spain",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Diagnostics & Research",
    "long_name": "Clínica Baviera, S.A.",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "CLINICA BAVIERA SA EO-,10",
    "state": null,
    "summary": "ClÃ­nica Baviera, S.A. operates a network of ophthalmological clinics. It is involved in the diagnosis, treatment, and monitoring of various types of ophthalmological disorders. The company's clinics offers myopia, hyperopia, astigmatism, presbyopia, cataract, retina, pediatric ophthalmology, glaucoma, squint, oculoplasty, cornea, neuroftalmologÃ­a, and vias lagrimales treatments, as well as refractive surgery services. It operates approximately 80 ophthalmological clinics in Spain, Germany, Austria, and Italy. The company is based in Madrid, Spain.",
    "website": "http://www.clinicabaviera.com",
    "zipcode": "28046"
  },
  "EEP.MC": {
    "city": "Corunna",
    "country": "Spain",
    "currency": "EUR",
    "exchange": "MCE",
    "industry": "Diagnostics & Research",
    "long_name": "Euroespes, S.A.",
    "market": "es_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "EUROESPES, S.A.",
    "state": null,
    "summary": "Euroespes, S.A., a medical center, provides medical services for the research, diagnosis, and treatment of central nervous system disorders and other diseases in Spain and internationally. It offers personalized and genomic medicine services for predictive, diagnostic, and therapeutic purposes. The company also provides medical services, such as digital diagnosis, neuro-psychology, neuro-otolaryngology, neuro-ophthalmology, nursing, radioa diagnosis, and laboratory services. In addition, it offers pharmacogenetic cards; biotechnology; and a range of nutraceuticals. The company was founded in 1991 and is based in Corunna, Spain.",
    "website": "http://www.euroespes.com",
    "zipcode": "15165"
  },
  "PANG.MC": {
    "city": "Barcelona",
    "country": "Spain",
    "currency": "EUR",
    "exchange": "MCE",
    "industry": "Diagnostics & Research",
    "long_name": "Pangaea Oncology, S.A.",
    "market": "es_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "PANGAEA ONCOLOGY S.A.",
    "state": null,
    "summary": "Pangaea Oncology, S.A., a medical services company, provides a range of services to cancer patients, and pharmaceutical and biotech clients worldwide. It offers molecular diagnostics, such as mutation analysis in tumor tissue and blood, gene amplification and translocation testing, immunohistochemistry, and gene expression; clinical trials; in vitro drug profiling, including MTT proliferation assays, Western blotting, colony formation, migration and invasion assays, and gene silencing; and Dx platform, which performs companion diagnostic platform validation, validation against commercially available platforms, and Ad-hoc R+D for diagnostics companies. The company also provides biomarker discovery to identify novel targets for targeted therapies in pre-clinical development. Pangaea Oncology, S.A. was founded in 2007 and is based in Barcelona, Spain.",
    "website": "http://www.panoncology.com",
    "zipcode": "08028"
  },
  "ZENO": {
    "city": "Valencia",
    "country": "Spain",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Diagnostics & Research",
    "long_name": "Zenosense, Inc.",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ZENOSENSE INC",
    "state": null,
    "summary": "Zenosense, Inc., through its joint venture, MIDS Medical Ltd., operates as a healthcare technology company. It develops MIDS Cardiac, a hand-held point of care cardiac diagnostic device targeting cardiac markers for the diagnosis of heart attack and cardiac related illnesses. The company was formerly known as Braeden Valley Mines, Inc. and changed its name to Zenosense, Inc. in November 2013. Zenosense, Inc. was founded in 2008 and is headquartered in Valencia, Spain.",
    "website": "http://www.zenosense.com",
    "zipcode": "46015"
  }
}
